SYNGENESyngene International Limited
Healthcare · Diagnostics & Research · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SYNGENE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 28/100)
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
- • RSI: 35
- • MACD: bearish
Bull case
- • Debt/Equity: 0.09
- • Promoter holding: 52.9%
- • Valuation vs sector: P/E 48.6 vs sector 52.7
- • Volatility: 32% annualized
Bear case
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
- • RSI: 35
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: 1.8% YoY
- • Profit growth: -19.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹9.41). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.